If ever a US FDA advisory committee could be very dramatic but also just a complete formality, the review of Pfizer Inc.’s COVID vaccine slated for 10 December would fit that bill. The company announced it would file for emergency use authorization on the morning of 20 November, FDA announced that evening it had scheduled an advisory committee, and Operation Warp Speed chief science officer Moncef Slaoui went on TV on 22 November to say that the vaccine could be cleared the day after the advisory committee.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?